GlassScriptPhysician profile
Robert D Ballard
NPI 1255424347
$2,930.48
in general payments reported to CMS, 2019-2025
28 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $273 · 2021: $590 · 2022: $547 · 2023: $20.17 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $44.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $44.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $500.67 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $408.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $333.54 | 2019-2025 | Arexvy, Shingrix |
| Grifols USA, LLC | $211.74 | 2019-2022 | |
| United Therapeutics Corporation | $107.31 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $101.96 | 2019 | |
| Mylan Specialty L.P. | $82.01 | 2019 | |
| Jazz Pharmaceuticals INC. | $78.25 | 2019-2021 | |
| Optinose US, INC. | $69.88 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $60.54 | 2019-2021 | |
| Shire North American Group INC | $59.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.78 | 2019 | |
| Genzyme Corporation | $58.77 | 2019-2021 | |
| Philips North America LLC | $48.49 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $37.74 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $33.15 | 2019 | |
| Circassia INC. | $31.59 | 2019 | |
| Merck Sharp & Dohme LLC | $29.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.28 | 2019-2020 | |
| Resmed Corp | $24.78 | 2019 | |
| Advanced Respiratory, INC | $21.11 | 2019 | |
| Zoll Respicardia, INC. | $20.17 | 2023 | Remede System |
| Nevro Corp. | $19.87 | 2019 | |
| Baxter Healthcare | $17.11 | 2022 | |
| Gilead Sciences, INC. | $13.05 | 2019 | |
| Biogen, INC. | $12.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.